Compare Herbalife Nutrition Ltd (HLF) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Herbalife Nutrition Ltd vs Vertex Pharmaceuticals Incorporated — how do they compare? Herbalife Nutrition Ltd trades at $12.77 (market cap $1.34B), while Vertex Pharmaceuticals Incorporated trades at $507.8 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 95.2× Herbalife Nutrition Ltd's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Herbalife Nutrition Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Herbalife Nutrition Ltd for 43 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| HLF | VRTX | |
|---|---|---|
Market Cap | $1.34B | $127.55B |
Volume | 1,589,457 | 1,487,944 |
Sector | Consumer Staples | Health |
52-Week High | $19.96 | $557.96 |
52-Week Low | $7.75 | $407.37 |
Typical Hold Time | 43 Days | 120 Days |
Enterprise Value | $3.18B | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HLF trades at $12.65, up 0.56% today, with a bullish technical signal from moving averages. The stock shows attractive valuation with a P/E of 8.22 and P/S of 0.26. Recent earnings were mixed, with a Q1 2026 beat but Q4 2025 and Q2 2026 misses. The company announced a $250 million share repurchase program and a CEO transition effective October 31, 2026. Cash flow trends show improvement, with 2026 projected net cash flow turning positive at $50 million.
The outlook is cautiously optimistic, supported by analyst consensus price target of $19.00 implying significant upside. Key opportunities include debt reduction progress and margin expansion plans. Risks include inconsistent earnings performance, high debt levels, and investor scrutiny following the CEO transition. The stock remains a value play if execution improves.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Herbalife Nutrition Ltd
Herbalife Nutrition Ltd is an international nutrition company.
Read more on HLF →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
